+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Immune Checkpoint Inhibitor"

From
Malignant Mesothelioma Market - Global Forecast 2026-2032 - Product Thumbnail Image

Malignant Mesothelioma Market - Global Forecast 2026-2032

  • Report
  • July 2026
  • 195 Pages
  • Global
From
Kaposi Sarcoma Market - Global Forecast 2026-2032 - Product Thumbnail Image

Kaposi Sarcoma Market - Global Forecast 2026-2032

  • Report
  • July 2026
  • 187 Pages
  • Global
From
Interferon Market - Global Forecast 2026-2032 - Product Thumbnail Image

Interferon Market - Global Forecast 2026-2032

  • Report
  • July 2026
  • 181 Pages
  • Global
From
From
From
From
From
From
Antineoplastic Agents Market - Global Forecast 2026-2032 - Product Thumbnail Image

Antineoplastic Agents Market - Global Forecast 2026-2032

  • Report
  • January 2026
  • 193 Pages
  • Global
From
CD40 Ligand Market - Global Forecast 2026-2032 - Product Thumbnail Image

CD40 Ligand Market - Global Forecast 2026-2032

  • Report
  • January 2026
  • 188 Pages
  • Global
From
Oncolytic Virus Therapies Market - Global Forecast 2026-2032 - Product Thumbnail Image

Oncolytic Virus Therapies Market - Global Forecast 2026-2032

  • Report
  • January 2026
  • 183 Pages
  • Global
From
From
From
From
Stomach Cancer Treatment Market - Global Forecast 2026-2032 - Product Thumbnail Image

Stomach Cancer Treatment Market - Global Forecast 2026-2032

  • Report
  • July 2026
  • 195 Pages
  • Global
From
From
From
Loading Indicator

Immune Checkpoint Inhibitor drugs are a type of immunotherapy used to treat immune disorders. They work by blocking proteins that act as “checkpoints” in the immune system, allowing the body to recognize and attack cancer cells. These drugs are used to treat a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. They are also used to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease. Immune Checkpoint Inhibitor drugs are a relatively new form of treatment, and the market is still in its early stages. However, the potential of these drugs has led to a surge in research and development, with many companies investing in the development of new drugs. Some of the major companies in the Immune Checkpoint Inhibitor market include Bristol-Myers Squibb, Merck, AstraZeneca, Roche, and Novartis. Other companies such as Pfizer, AbbVie, and Johnson & Johnson are also involved in the development of these drugs. Show Less Read more